Publications

5891 Results

Predicting Non-Fatal Toxicities with 7+3 Induction Chemotherapy in Adult Acute Myeloid Leukemia: Analysis of SWOG Trial S1203

Authors
M Othus;G Garcia-Manero;F Appelbaum;HP Erba;R Walter
Journal / Conference
Blood 132:1403; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), poster
Year
2018
Research Committee(s)
Leukemia
Study Number(s)
S1203

Bortezomib, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777 with Long-Term Follow Up

Authors
BGM Durie;A Hoering;R Sexton;M Abidi;J Epstein;SV Rajkumar;A Dispenzieri;S Kahanic;M Thakuri;F Reu;CR Reynolds;RZ Orlowski;B Barlogie
Journal / Conference
Blood 132:1992; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), poster
Year
2018
Research Committee(s)
Myeloma
Study Number(s)
S0777

Prospective Study of Minimal Residual Disease (MRD) Status and Outcome After Complete Remission (CR) Following Intensive Remission Induction Therapy in Older Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age > 60 Years

Authors
J Foran;E Paietta;X Sun;J Racevskis;D Claxton;H Lazurus;M Thomas;A Melnick;R Levine;D Arber;Y Zhang;J Rowe;JE Godwin;J Altman;A Al-Kali;H Zheng;K Pratz;ER Broun;B Powell;K O'Dwyer;M Tallman;S Luger;M Litzow
Journal / Conference
Blood 132:437; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), accepted, oral/plenary
Year
2018
Research Committee(s)
Leukemia
Study Number(s)
CTSU/E2906

FLT3-ITD Mutations Are Prevalent in Older Adults with Acute Myeloid Leukemia (AML) and Significantly Impact Outcome After Intensive Therapy: Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age > 60 Years

Authors
J Foran;X Sun;E Paietta;J Racevskis;D Claxton;H Lazurus;D Arber;Y Zhang;J Rowe;J Godwin;J Altman;A Al-Kali;H Zheng;ER Broun;B Powell;K O'Dwyer;M Tallman;M Litzow;J Pratz;S Luger
Journal / Conference
Blood 132:3995American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), poster
Year
2018
Research Committee(s)
Leukemia
Study Number(s)
CTSU/E2906

Prognostic impact of insertion site in acute myeloid leukemia with FLT3 internal tandem duplication: results from the RATIFY study (Alliance)

Authors
F Rucker;L Du;T Blatte;J Krzykalla;I Gathmann;RA Larson;F Lo-Coco;S Amadori;T Prior;J Brandwein;F Appelbaum;B Medeiros;M Tallman;J Sierra;E Tiecke;C Pallaud;M Sanz;T de Witte;D Niederwieser;G Ehninger;M Heuser;M Ganser;L Bullinger;C Bloomfield;RM Stone;H Dohner;C Thiede;K Dohner
Journal / Conference
Blood 132:435; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA)
Year
2018
Research Committee(s)
Leukemia
Study Number(s)
CTSU/C10603

Comprehensive molecular profiling of FLT3-mutated acute myeloid leukemia (AML) patients treated within the RATIFY trial

Authors
N Jahn;N Panina;L Bullinger;A Dolnick;J Herzig;T Blatte;A Benner;J Krzykalla;I Gathmann;RA Larson;F Lo-Coco;S Amadori;T Prior;J Brandwein;F Appelbaum;B Medeiros;M Tallman;E Tiecke;C Pallaud;G Ehninger;M Heuser;A Ganser;RM Stone;C Thiede;H Dohner;C Bloomfield;K Dohner
Journal / Conference
Blood 132:1534; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), poster
Year
2018
Research Committee(s)
Leukemia
Study Number(s)
CTSU/C10603

RATIFY: Prognostic Impact of FLT3 Tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy

Authors
M Voso;RA Larson;T Prior;G Marcucci;D Jones;J Krauter;M Heuser;S Lavorgna;J Nomdedeu;K Laumann;S Geyer;R Klisovic;A Wei;J Sierra;M Sanz;J Brandwein;T de Witte;JH Jansen;D Niederwieser;F Appelbaum;B Medeiros;M Tallman;R Schlenk;A Ganser;H Serve;G Ehninger;S Amadori;Y Cheng;I Gathmann;E Tiecke;C Thiede;K Dohner;H Dohner;RM Stone;C Bloomfield;F Lo-Coco
Journal / Conference
Blood 132:2668; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), poster
Year
2018
Research Committee(s)
Leukemia
Study Number(s)
CTSU/C10603

African-American Patients with Monoclonal Gammopathy Have a Reduced Risk of Transformation to Clinical Myeloma. Results of a Prospective Study SWOG S0120

Authors
M Dhodapkar;R Sexton;A Hoering;B Barlogie;R Orlowski
Journal / Conference
Blood 132:1877; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), poster
Year
2018
Research Committee(s)
Myeloma
Study Number(s)
S0120

Analysis of Accrual Patterns of Adolescent & Young Adult (AYA) Patients to A National Cooperative Research Group Over 25 Years: The SWOG Experience

Authors
MA Lewis;RKH Johnson;C Nichols;D Hershman;J Unger
Journal / Conference
Global Adolescent & Young Adult Cancer Congress (Dec 4-6, 2018, Sydney, Australia), oral presentation
Year
2018
Research Committee(s)
Cancer Care Delivery

A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)

Authors
T Shanafelt;V Wang;N Kay;C Hanson;S O'Brien;J Barrientos;H Erba;R Stone;M Litzow;M Tallman
Journal / Conference
Blood 132:LBA-4; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), oral
Year
2018
Research Committee(s)
Leukemia
Study Number(s)
CTSU/E1912